

REP 1001 (SEQ ID NO : 1) vs HSV-1




FIG. 1a

REP 2001 (SEQ ID NO: 2) vs HSV-1




FIG. 1b

REP 3007 (SEQ ID NO: 3) vs HSV-1




FIG. 1c

FIG. 3a




FIG. 3b




FIG. 3c





FIG. 3d



REP 2016 (SEQ ID NO: 4) vs HSV-1




FIG. 8d

REP 2017 (SEQ ID NO: 5) vs HSV-1




FIG. 8e

REP 2018 (SEQ ID NO: 6) vs HSV-1




FIG. 8f

REP 2019 (SEQ ID NO: 7) vs HSV-1




FIG. 8g

REP 2020 (SEQ ID NO: 8) vs HSV-1




FIG. 8h

REP 2121 (SEQ ID NO: 9) vs HSV-1




FIG. 8i

Rep 1001 (SEQ ID NO: 1) vs HSV-2




FIG. 12a

REP 2001 (SEQ ID NO: 2) vs HSV-2




FIG. 12b

REP 3007 (SEQ ID NO: 3) vs HSV-2




FIG. 12c

FIG. 14a




FIG. 14b




FIG. 14c





FIG. 14d






FIG. 17g




FIG. 17h





FIG. 17i

**FIG. 33**

Single and double stranded PS-ODNs can bind both HSV-1 and HIV-1 lysates




FIG. 35a




FIG. 35b




FIG. 35c

SEQUENCE COMPOSITION VS ANTI-HSV EFFICACY




FIG. 37a

Effect of sequence composition on efficiency against HSV-1




FIG. 37b